|
3.1 Tabac
|
|
|
|
|
3.6 Prévention - Activité physique
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
5. Traitements
|
|
|
|
5.2 Pharma
|
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
|
|
|
|
New treatment for rare white blood cell cancer [EMA]
|
|
|
|
|
|
The
European Medicines Agency (EMA) has recommended extending the
authorised indication of Gazyvaro (obinutuzumab) to treat patients with
follicular lymphoma. The medicine is to be used in combination with
bendamustine in patients who were previously treated with chemotherapy.
|
|
|
|
|
|
|
6.10 Politiques
|
|
|
The Moonshot: A View from Europe [The Cancer Letter]
|
|
|
|
|
|
Global
society should not have to depend on the United States alone to solve
one of the great problems of our times: the European Union at least
should volunteer to share the financial burden (not to dilute federal
government contributions by cost-sharing, but to add additional matching
funds).
|
|
|
|
|
|
|
|
|
6.6 Publications
|
|
|
Step by Step: Collecting and Connecting ORCID iDs in the Publishing Process [ORCID]
|
|
|
|
|
|
Identifiers
are a package deal: they need to be integrated into standard research
workflows in a way that reinforces a familiar user experience, does not
add to researcher workload, uses best practices including authenticated
collection, and provides benefits to all parties. These benefits include
increased data processing automation, reduced administrative burden,
and improved search accuracy and discoverability.
|
|
|
|
|
|
|
|
6.8 Communication
|
|
|